Literature DB >> 27091711

Making Radiation Therapy for Prostate Cancer More Economical and More Convenient.

Anthony L Zietman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27091711     DOI： 10.1200/JCO.2016.67.3764

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Challenges in the Analysis of Outcomes for Surgical Compared to Radiotherapy Treatment of Prostate Cancer.

Authors:  Scott M Glaser; Ronny Kalash; Dante R Bongiorni; Mark S Roberts; Goundappa K Balasubramani; Bruce L Jacobs; Sushil Beriwal; Dwight E Heron; Joel S Greenberger
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

2.  Acute toxicity of image-guided hypofractionated proton therapy for localized prostate cancer.

Authors:  Koichiro Nakajima; Hiromitsu Iwata; Hiroyuki Ogino; Yukiko Hattori; Shingo Hashimoto; Mikiko Nakanishi; Toshiyuki Toshito; Yukihiro Umemoto; Shoichiro Iwatsuki; Yuta Shibamoto; Jun-Etsu Mizoe
Journal:  Int J Clin Oncol       Date:  2017-11-02       Impact factor: 3.402

3.  Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.

Authors:  Trevor J Royce; Panayiotis Mavroidis; Kyle Wang; Aaron D Falchook; Nathan C Sheets; Donald B Fuller; Sean P Collins; Issam El Naqa; Daniel Y Song; George X Ding; Alan E Nahum; Andrew Jackson; Jimm Grimm; Ellen Yorke; Ronald C Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-09-06       Impact factor: 8.013

4.  Editorial Comment: Ultra-hypofractionated versus conventionally fractionated radiothe-rapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.

Authors:  Felipe Lott
Journal:  Int Braz J Urol       Date:  2020 Nov-Dec       Impact factor: 1.541

5.  Planning feasibility of extremely hypofractionated prostate radiotherapy on a 1.5 T magnetic resonance imaging guided linear accelerator.

Authors:  Mariska D den Hartogh; Hans C J de Boer; Eline N de Groot-van Breugel; Jochem R N van der Voort van Zyp; Jochem Hes; Uulke A van der Heide; Floris Pos; Karin Haustermans; Tom Depuydt; Robert Jan Smeenk; Martina Kunze-Busch; Bas W Raaymakers; Linda G W Kerkmeijer
Journal:  Phys Imaging Radiat Oncol       Date:  2019-07-15

6.  Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer.

Authors:  Pedro C Lara; Juan I Rodríguez-Melcón; Amalia Palacios-Eito; Antonio Lozano; Asunción Hervás-Morón; Elena Villafranca; Alfonso Gómez-Iturriaga; Gemma Sancho; Xavier Maldonado
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.